Alberto Pilotto1, Pietro Gallina2, Massimiliano Copetti3, Andrea Pilotto4, Francesco Marcato2, Anna M Mello1, Matteo Simonato2, Giancarlo Logroscino5,6, Alessandro Padovani4, Luigi Ferrucci7, Francesco Panza3,5. 1. Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Frailty Area, E.O. Galliera Hospital of National Relevance and High Specialization, Genova, Italy. 2. Azienda Unità Locale Socio Sanitaria 16 Padova, S. Antonio Hospital, Padova, Italy. 3. Unit of Biostatistics, Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. 4. Clinic of Neurology, University of Brescia, Brescia, Italy. 5. Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, Bari, Italy. 6. Department of Clinical Research in Neurology, University of Bari Aldo Moro, Lecce, Italy. 7. National Institute on Aging, Baltimore, Maryland.
Abstract
OBJECTIVES: To investigate the relationship between warfarin treatment and different strata of all-cause mortality risk assessed using the Multidimensional Prognostic Index (MPI) based on information collected using the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) in community-dwelling older adults with atrial fibrillation (AF). DESIGN: Retrospective observational study. SETTING: Older community-dwelling adults who underwent a SVaMA evaluation establishing accessibility to homecare services and nursing home admission from 2005 to 2013 in the Padova Health District, Italy. PARTICIPANTS: Community-dwelling individuals with AF aged 65 and older (N = 1,827). MEASUREMENTS: Participants were classified as being at mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), or severe (MPI-SVaMA-3) risk of mortality using the MPI-SVaMA, a validated prognostic tool based on age, sex, comorbidity, cognitive status, mobility and functional disability, pressure sore risk, and social support. The association between warfarin treatment and mortality was tested using multivariate- and propensity score-adjusted Cox regression models, controlling for age, sex, all SVaMA domains, concomitant diseases, and drug treatments. RESULTS: Higher MPI-SVaMA scores were associated with lower rates of warfarin treatment and higher 3-year mortality. After adjustment for propensity score quintiles, warfarin treatment was significantly associated with lower 2-year mortality in individuals with MPI-SVaMA-1 (hazard ratio (HR) = 0.64, 95% confidence interval (CI) = 0.50-0.82), MPI-SVaMA-2 (HR = 0.68, 95% CI = 0.55-0.85), and MPI-SVaMA-3 (HR = 0.55, 95% CI = 0.44-0.67). Heterogeneity analyses confirmed that the effect of warfarin treatment was not different between MPI-SVaMA groups (P for heterogeneity = .48). CONCLUSION: Community-dwelling older adults with AF benefitted from anticoagulation in terms of lower all-cause mortality over a mean follow-up of 2 years, regardless of poor health and functional condition. Although this benefit can be ascribed to the treatment, it may also reflect better overall care.
OBJECTIVES: To investigate the relationship between warfarin treatment and different strata of all-cause mortality risk assessed using the Multidimensional Prognostic Index (MPI) based on information collected using the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA) in community-dwelling older adults with atrial fibrillation (AF). DESIGN: Retrospective observational study. SETTING: Older community-dwelling adults who underwent a SVaMA evaluation establishing accessibility to homecare services and nursing home admission from 2005 to 2013 in the Padova Health District, Italy. PARTICIPANTS: Community-dwelling individuals with AF aged 65 and older (N = 1,827). MEASUREMENTS: Participants were classified as being at mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), or severe (MPI-SVaMA-3) risk of mortality using the MPI-SVaMA, a validated prognostic tool based on age, sex, comorbidity, cognitive status, mobility and functional disability, pressure sore risk, and social support. The association between warfarin treatment and mortality was tested using multivariate- and propensity score-adjusted Cox regression models, controlling for age, sex, all SVaMA domains, concomitant diseases, and drug treatments. RESULTS: Higher MPI-SVaMA scores were associated with lower rates of warfarin treatment and higher 3-year mortality. After adjustment for propensity score quintiles, warfarin treatment was significantly associated with lower 2-year mortality in individuals with MPI-SVaMA-1 (hazard ratio (HR) = 0.64, 95% confidence interval (CI) = 0.50-0.82), MPI-SVaMA-2 (HR = 0.68, 95% CI = 0.55-0.85), and MPI-SVaMA-3 (HR = 0.55, 95% CI = 0.44-0.67). Heterogeneity analyses confirmed that the effect of warfarin treatment was not different between MPI-SVaMA groups (P for heterogeneity = .48). CONCLUSION: Community-dwelling older adults with AF benefitted from anticoagulation in terms of lower all-cause mortality over a mean follow-up of 2 years, regardless of poor health and functional condition. Although this benefit can be ascribed to the treatment, it may also reflect better overall care.
Authors: Alberto Pilotto; Pietro Gallina; Andrea Fontana; Daniele Sancarlo; Salvatore Bazzano; Massimiliano Copetti; Stefania Maggi; Giulia Paroni; Francesco Marcato; Fabio Pellegrini; Daniele Donato; Luigi Ferrucci Journal: J Am Med Dir Assoc Date: 2013-02-09 Impact factor: 4.669
Authors: Elaine M Hylek; James D'Antonio; Carmella Evans-Molina; Carol Shea; Lori E Henault; Susan Regan Journal: Stroke Date: 2006-03-09 Impact factor: 7.914
Authors: Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245
Authors: Alberto Pilotto; Franco Rengo; Niccolò Marchionni; Daniele Sancarlo; Andrea Fontana; Francesco Panza; Luigi Ferrucci Journal: PLoS One Date: 2012-01-11 Impact factor: 3.240
Authors: Alberto Pilotto; Maria Cristina Polidori; Nicola Veronese; Francesco Panza; Rosa Arboretti Giancristofaro; Andrea Pilotto; Julia Daragjati; Eleonora Carrozzo; Camilla Prete; Pietro Gallina; Alessandro Padovani; Stefania Maggi Journal: J Am Med Dir Assoc Date: 2017-10-12 Impact factor: 4.669
Authors: Janet Sultana; Ingrid Leal; Marcel de Wilde; Maria de Ridder; Johan van der Lei; Miriam Sturkenboom; Gianluca Trifiro' Journal: Drug Saf Date: 2019-06 Impact factor: 5.606
Authors: Nicola Veronese; Brendon Stubbs; Marianna Noale; Marco Solmi; Alberto Pilotto; Alberto Vaona; Jacopo Demurtas; Christoph Mueller; Jonathan Huntley; Gaetano Crepaldi; Stefania Maggi Journal: J Am Med Dir Assoc Date: 2017-04-07 Impact factor: 4.669
Authors: Qiaoxi Chen; Kate Lapane; Anthony P Nunes; Jennifer Tjia; Julie Hugunin; Matthew Alcusky Journal: J Clin Pharm Ther Date: 2021-08-31 Impact factor: 2.145
Authors: Alberto Pilotto; Carlo Custodero; Stefania Maggi; Maria Cristina Polidori; Nicola Veronese; Luigi Ferrucci Journal: Ageing Res Rev Date: 2020-03-21 Impact factor: 10.895
Authors: Daniel M Bean; James Teo; Honghan Wu; Ricardo Oliveira; Raj Patel; Rebecca Bendayan; Ajay M Shah; Richard J B Dobson; Paul A Scott Journal: PLoS One Date: 2019-11-25 Impact factor: 3.240